Neem leaf extract induces cell death by apoptosis and autophagy in B-chronic lymphocytic leukemia cells. Issue 3 (March 2014)

• Record Type: Journal Article
• Authors: Chitta, Kasyapa S.; Khan, A. Nazmul H.; Ersing, Noreen; Swaika, Abhisek; Masood, Aisha; Paulus, Aneel; Qadeer, Abdul; Advani, Pooja; Sher, Taimur; Miller, Kena C.; Lee, Kelvin; Chanan-Khan, Asher A.
• Is Part Of: Leukemia & lymphoma. Volume 55:Issue 3(2014:Mar.)
• Page Start: 652
• Page End: 661
• Publication Date: 2014-03
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2013.807927
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>Chronic lymphocytic leukemia (CLL) is the most common adult leukemia and is currently incurable. To expand the therapeutic armamentarium, we investigated neem leaf extract (NLE) after a patient with CLL demonstrated disease regression upon taking oral NLE. NLE-mediated apoptosis was examined in peripheral blood mononuclear cells (PBMCs) from 41 patients with CLL. NLE induced a dose-dependent reduction in CLL cell viability with significant apoptosis observed at 0.06% (w/v) by 24 h. Annexin-V staining and poly(ADP-ribose) polymerase 1 (PARP-1) and caspase 3 cleavage were observed after NLE treatment. However, a pan-caspase inhibitor only partially blocked NLE-mediated cell death. NLE also caused loss of mitochondrial outer membrane permeability and nuclear translocation of apoptosis-inducing factor. Furthermore, NLE treatment resulted in LC3-I cleavage. Biochemical analyses revealed that NLE also inhibits Bcl-2 and p53 proteins. In summary, NLE exhibits anti-leukemic properties in patient primary CLL cells and demonstrates clinical efficacy, warranting further investigation as a potential therapy for CLL.</p> </abstract>